Campion Asset Management’s Sonnet BioTherapeutics SONN Stock Holding History

Campion Asset Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-37	Closed	-$25K	–	91
2022 Q2	$25K	Hold	37	–	–	0.02%	92
2022 Q1	$34K	Buy	+37	New	+$31.3K	0.03%	92

Other funds holding SONN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Campion Asset Management's SONN Position: Q3 2022 in Review

Campion Asset Management sold out of Sonnet BioTherapeutics (SONN) in Q3 2022, closing a stake of 37 shares — an estimated $25K sold.

Campion Asset Management first reported a position in SONN in Q1 2022 and held it in 2 quarters. The position peaked at $34K in Q1 2022. 10 funds tracked by Wall St. Rank hold SONN as of Q3 2022.

Campion Asset Management reported no remaining Sonnet BioTherapeutics position as of Q3 2022 after selling out during the quarter.
Campion Asset Management sold 37 Sonnet BioTherapeutics shares in Q3 2022, an estimated $25K.
Campion Asset Management first reported a position in Sonnet BioTherapeutics in Q1 2022 and held it in 2 quarters.
Campion Asset Management's Sonnet BioTherapeutics position peaked at $34K in Q1 2022.
10 funds tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q3 2022.

Based on Campion Asset Management's 13F filing for Q3 2022, filed 10 Nov 2022.